Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells

(2014) Glenna Wink Foight et al.   ACS Chemical Biology

Triple-Negative Breast Carcinoma

(2014) Robert Schmadeka et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells

(2014) S Colak et al.   CELL DEATH AND DIFFERENTIATION

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1

(2013) Z Zhang et al.   BRITISH JOURNAL OF CANCER

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells

(2013) Fabio Petrocca et al.   CANCER CELL

Therapeutic targets in triple negative breast cancer

(2013) Sandra A O'Toole et al.   JOURNAL OF CLINICAL PATHOLOGY

BH3 profiling in whole cells by fluorimeter or FACS

(2013) Jeremy Ryan et al.   METHODS

BH3 Mimetics: Status of the Field and New Developments

(2013) C. Billard   MOLECULAR CANCER THERAPEUTICS

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Triple-negative breast cancer: making the most of a misnomer

(2012) Nicole MCCARTHY et al.   Asia-Pacific Journal of Clinical Oncology

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

(2012) Guo Wei et al.   CANCER CELL

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B

(2012) R W Rooswinkel et al.   Cell Death & Disease

An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737

(2011) S. Al-harbi et al.   BLOOD

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

(2011) J. M. Tromp et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Contagious Cancer

(2011) J. S. Welsh   ONCOLOGIST

Directed Therapy of Subtypes of Triple-Negative Breast Cancer

(2011) L. A. Carey   ONCOLOGIST

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

(2010) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Mcl-1; the molecular regulation of protein function

(2010) Luke W. Thomas et al.   FEBS LETTERS

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

(2010) H Zhang et al.   ONCOGENE

BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists

(2009) K C Goldsmith et al.   CELL DEATH AND DIFFERENTIATION

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Down-Regulation of Mcl-1 by Small Interfering RNA Sensitizes Resistant Melanoma Cells to Fas-Mediated Apoptosis

(2008) N. Chetoui et al.   MOLECULAR CANCER RESEARCH

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY